Search

Your search keyword '"Shargian, Liat"' showing total 180 results
Start Over Author "Shargian, Liat"
180 results on '"Shargian, Liat"'

3. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma

Author

Fried, Shalev, Shouval, Roni, Walji, Moneeza, Flynn, Jessica R., Yerushalmi, Ronit, Shem-Tov, Noga, Danylesko, Ivetta, Tomas, Ana Alarcon, Fein, Joshua A., Devlin, Sean M., Sauter, Craig S., Shah, Gunjan L., Kedmi, Meirav, Jacoby, Elad, Shargian, Liat, Raanani, Pia, Yeshurun, Moshe, Perales, Miguel-Angel, Nagler, Arnon, Avigdor, Abraham, and Shimoni, Avichai

Published
2023
Full Text
View/download PDF

11. P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY

Author

Lebel, Eyal, primary, Kastritis, Efstathios, additional, Palladini, Giovanni, additional, Milani, Paolo, additional, Theodorakakou, Foteini, additional, Aumann, Shlomzion, additional, Lavi, Noa, additional, Shargian, Liat, additional, Magen, Hila, additional, Cohen, Yael, additional, Gatt, Moshe, additional, and Vaxman, Iuliana, additional

Published
2023
Full Text
View/download PDF

14. Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft‐vs‐host disease.

Author

Goldberg, Idan, Granot, Galit, Telerman, Alona, Partouche, Shirly, Shochat, Tzippy, Halperin, Erez, Gafter‐Gvili, Anat, Shargian, Liat, Yeshurun, Moshe, Raanani, Pia, Wolach, Ofir, and Yahalom, Vered

Subjects
GRAFT versus host disease, CHRONICALLY ill, LEUCOCYTE elastase, NEUTROPHILS
Abstract

Introduction: Extracorporeal photopheresis (ECP) is considered an effective treatment for patients with chronic graft vs host disease (cGVHD) and demonstrates efficacy in ameliorating GVHD. The mechanism by which ECP acts against cGVHD is not fully understood. Preliminary observations have hinted at the potential involvement of neutrophil extracellular traps (NETs) formation in the pathogenesis of cGVHD. We aimed to assess the influence of ECP on the formation of NETs in patients with cGVHD as a potential mechanism in this setting. Methods: Patients treated with ECP for cGVHD at the Rabin Medical Center were included in this study. Blood samples were obtained at three different time points: before starting an ECP cycle, at the end of the first day of treatment, and 24 h following the initiation of the ECP treatment cycle. Neutrophils were harvested from all blood samples. NET formation was assessed by measurement of NET‐bound specific neutrophil elastase activity and by immunofluorescence staining. Results: Six patients (two females and four males) with cGVHD were included in the study. We observed a significant increase in NET formation among all six patients following ECP. Net‐bound specific neutrophil elastase activity was elevated from a median value of 2.23 mU/mL (interquartile range [IQR] 2.06‐2.47 mU/mL) at baseline to a median value of 13.06 mU/mL (IQR 10.27‐15.97 mU/mL) immediately after the treatment and to a peak median value of 14.73 mU/mL (IQR 9.6‐22.38 mU/mL) 24 h following the initiation of the ECP cycle. A qualitative assessment of NET formation using immunofluorescence staining has demonstrated markedly increased expression of citrullinated histone H3, a marker of NET formation, following ECP treatment. Conclusions: Our preliminary data indicate that ECP induces NET formation among patients with cGVHD. The contribution of increased NET formation to the therapeutic effect of cGVHD should be further investigated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Combined Kidney and Hematopoietic Cell Transplantation for Tolerance Induction between HLA Matched Sibling Donor-Recipient Pairs

Author

Yeshurun, Moshe, primary, Rachamimov, Ruth, additional, Shargian, Liat, additional, Fenig, Eyal, additional, Pasvolsky, Oren, additional, Raanani, Pia, additional, Sela-Navon, Michal, additional, Pearl-Yafe, Michal, additional, Stein, Jerry, additional, Mor, Eitan, additional, Israeli, Moshe, additional, and Nesher, Evyatar, additional

Published
2023
Full Text
View/download PDF

21. Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience

Author

Grisariu Greenzaid, Sigal, primary, Ram, Ron, additional, Kazuli, Mona, additional, Yehudai-Ofir, Dana, additional, Shargian, Liat, additional, Zuckerman, Tsila, additional, Yeshurun, Moshe, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Zimran, Eran, additional, Shaulov, Adir, additional, Stepensky, Polina, additional, Strahilevitz, Jacob, additional, and Avni, Batia, additional

Published
2022
Full Text
View/download PDF

23. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study

Author

Shargian, Liat, primary, Amit, Odelia, additional, Bernstine, Hanna, additional, Gurion, Ronit, additional, Gafter‐Gvili, Anat, additional, Rozovski, Uri, additional, Pasvolsky, Oren, additional, Perets, Galit, additional, Horowitz, Netanel A., additional, Halloun, Jabour, additional, Perry, Chava, additional, Avivi, Irit, additional, Raanani, Pia, additional, Yeshurun, Moshe, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

28. Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study.

Author

Lebel, Eyal, Kastritis, Efstathios, Palladini, Giovanni, Milani, Paolo, Theodorakakou, Foteini, Aumann, Shlomzion, Lavi, Noa, Shargian, Liat, Magen, Hila, Cohen, Yael, Gatt, Moshe E., and Vaxman, Iuliana

Subjects
THERAPEUTIC use of antineoplastic agents, RESEARCH, AMYLOIDOSIS, INTERNATIONAL relations, CONFIDENCE intervals, CHRONIC diseases, CANCER relapse, RETROSPECTIVE studies, TREATMENT effectiveness, TUMOR lysis syndrome, DISEASE prevalence, DESCRIPTIVE statistics, LYMPHOPROLIFERATIVE disorders, MEDICAL prescriptions, PROGRESSION-free survival, LONGITUDINAL method, DRUG resistance in cancer cells, OVERALL survival
Abstract

Simple Summary: Light-chain amyloidosis is a rare disease, and treatment for relapsed light-chain amyloidosis patients is an unmet need. Venetoclax is an oral medication that has proven great efficacy in many hematological cancers, including multiple myeloma. Venetoclax is considered a promising agent for the treatment of relapsed light-chain amyloidosis. We aimed to report the outcomes of therapy in 26 relapsed light-chain amyloidosis patients treated with venetoclax. We found a very high response rate (88%), and most responses were deep and prolonged. Treatment was effective even when doses were reduced. Venetoclax treatment was safe, and one patient died due to infection. These promising results require confirmation in a randomized trial. Therapeutic options in relapsed refractory (R/R) light-chain (AL) amyloidosis patients are limited. Given the encouraging results in t(11;14) multiple myeloma and the high prevalence of t(11;14) in AL amyloidosis, venetoclax is an attractive treatment option in this setting. We report here the results of a multi-center retrospective study on 26 R/R AL amyloidosis patients treated off-label with venetoclax. The median lines of therapy prior to venetoclax was 3.5 (range 1–7), and 88% of our cohort had t (11;14). Twenty-two patients (85%) were previously treated with daratumumab. The overall hematologic response rate was 88%, 35% achieved a CR, and 35% achieved VGPR. The median event-free survival was 25 months (m) (95% CI 9.7 m-not reached), and the median overall survival was 33 m (95% CI 25.9–39.2 m). Most of the patients in this cohort are in ongoing deep responses and continuing venetoclax therapy. The treatment was relatively safe. One patient died due to infection, and there were two grade 3 infections in our cohort. Tumor lysis syndrome (TLS) was not seen in any patient. Dose reductions were frequent but did not affect the efficacy. These promising results require confirmation in a randomized controlled trial. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.

Author

Shargian, Liat, Amit, Odelia, Bernstine, Hanna, Gurion, Ronit, Gafter‐Gvili, Anat, Rozovski, Uri, Pasvolsky, Oren, Perets, Galit, Horowitz, Netanel A., Halloun, Jabour, Perry, Chava, Avivi, Irit, Raanani, Pia, Yeshurun, Moshe, and Ram, Ron

Subjects
*DISEASE relapse, *DIFFUSE large B-cell lymphomas, *STEM cell transplantation, *HEMATOPOIETIC stem cell transplantation, *SALVAGE therapy, *PROGRESSION-free survival
Abstract

Objectives: To evaluate the role of additional chemotherapy before autologous hematopoietic cell transplantation (HCT) in patients with relapse/refractory diffuse large B‐cell lymphoma (DLBCL) who achieve partial remission following first salvage therapy. Methods: We conducted a multicenter retrospective study of all adult patients with DLBCL who underwent HCT between 2008 and 2020 and achieved partial response (PR) after the first salvage and were either referred directly to HCT (n = 47) or received additional salvage therapy before HCT (n = 22). Results: Post‐HCT CR rate and progression‐free survival were comparable between the two groups (66% vs. 68%, p =.86 and median not reached vs. 10.2 months [95% confidence interval, CI 7.1–12.3], p =.27, respectively). Median overall survival (OS) and estimated 3‐year OS favored patients who were directly referred to HCT (105.8 [95% CI 63–148] months vs. 14.5 [95% CI 0–44] months, p =.035, and 65% [95% CI 51%–75%] vs. 40% [95% CI 21%–53%], p =.035, respectively). In Cox regression model, while International Prognostic Index and primary refractory versus relapse disease did not impact OS, allocation to a second salvage regimen and older age were both associated with inferior survival (hazard ratio [HR] = 2.57 95% CI 1.1–5.8, p =.023 and HR = 1.04 95% CI 0.99–1.2, p =.064, respectively). Conclusions: Referring patients with chemotherapy‐sensitive disease in PR directly to HCT is associated with better OS compared to those receiving additional lines of treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations.

Author

Atamna, Alaa, Yeshurun, Moshe, Shargian, Liat, Raanani, Pia, Kramer, Mordechai, Zvi, Haim Ben, Ami, Ronen Ben, Marr, Kieren A, and Bishara, Jihad

Subjects
PULMONARY aspergillosis, ASPERGILLUS fumigatus, VORICONAZOLE, GALACTOMANNANS, GENETIC mutation
Abstract

This article discusses a case of fatal invasive pulmonary and cerebral aspergillosis caused by a triazole-resistant strain of Aspergillus fumigatus with multiple CYP51A mutations. Triazoles, such as voriconazole, are the primary treatment for invasive pulmonary aspergillosis, but triazole resistance in A. fumigatus has been increasing. The most common resistance mechanism is alterations in the CYP51A coding sequence or promoter. The patient in this case had autosomal recessive chronic granulomatous disease and had been treated with various antibiotics and voriconazole prophylaxis. Despite treatment with antifungal drugs, the patient's condition worsened and they eventually died. The isolated A. fumigatus strain had a CYP51A mutation with a 46 bp tandem repeat in the promoter and five amino acid substitutions in the coding sequence. This mutation has not been previously identified in clinical A. fumigatus isolates in Israel. It is unclear whether the mutated spores were acquired from the environment or due to prolonged voriconazole exposure. [Extracted from the article]

Published
2024
Full Text
View/download PDF

33. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study

Author

Pasvolsky, Oren, primary, Shimony, Shai, additional, Ram, Ron, additional, Shimoni, Avichai, additional, Shargian, Liat, additional, Avni, Batia, additional, Wolach, Ofir, additional, Shochat, Tzippy, additional, Yerushalmi, Ronit, additional, Amit, Odelia, additional, Raanani, Pia, additional, and Yeshurun, Moshe, additional

Published
2021
Full Text
View/download PDF

39. Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis

Author

Pasvolsky, Oren, Shimony, Shai, Yeshurun, Moshe, Shargian, Liat, Wolach, Ofir, Raanani, Pia, Gafter-Gvili, Anat, and Gurion, Ronit

Abstract

For patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), disease relapse remains the most common reason for transplant failure and patient death. Recent randomized controlled trials (RCTs) have aimed to reduce the risk of relapse by means of post-transplant maintenance therapy. We performed a systematic review and meta-analysis of RCTs comparing the efficacy and safety of maintenance with observation or placebo in patients with AML after allogeneic HSCT. We searched Cochrane Library, PubMed and conference proceedings up to Febuary 2021. Our search yielded five trials including 736 patients. Maintenance therapy consisted of tyrosine kinase inhibitors (TKIs) in 3 studies (sorafenib 2 studies; midostaurin 1 study) and hypomethylating agents (HMAs) in 2 studies (decitabine and azacytidine 1 study each). Maintenance therapy was associated with an improved overall survival (OS), HR = 0.61 (95% CI 0.47–0.80). Subgroup analysis revealed advantage in OS with either TKI or HMA maintenance. Relapse free survival (RFS) was also improved in the maintenance arm compared with the control arm HR = 0.51(95% CI 0.40 − 0.66). There was no difference between the two arms in overall grade 3/4 adverse events or overall infections, in grade 3/4 infections, or in acute and chronic graft versus host disease. Our meta-analysis shows that post-transplant maintenance therapy in AML patients is effective in improving RFS and OS, with a satisfactory safety profile.

Published
2021
Full Text
View/download PDF

40. Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation

Author

Pasvolsky, Oren, primary, Shargian, Liat, additional, Rozovski, Uri, additional, Wolach, Ofir, additional, Ram, Ron, additional, Shapira, Michael Y., additional, Avni, Batia, additional, Stepensky, Polina, additional, Israeli, Moshe, additional, Vidal-Fisher, Liat, additional, Shpilberg, Ofer, additional, Raanani, Pia, additional, and Yeshurun, Moshe, additional

Published
2021
Full Text
View/download PDF

41. Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study

Author

Shimony, Shai, primary, Yeshurun, Moshe, additional, Wolach, Ofir, additional, Ram, Ron, additional, Rozovski, Uri, additional, Shargian, Liat, additional, Zukerman, Tsila, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Krayem, Baher, additional, Avni, Batya, additional, Peretz, Galit, additional, Raanani, Pia, additional, and Pasvolsky, Oren, additional

Published
2021
Full Text
View/download PDF

42. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian, Liat, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Stepansky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

46. The Effect of Folinic Acid (FA) Rescue Following MTX Gvhd Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: A Double Blind Randomized Controlled Study

Author

Yeshurun, Moshe, primary, Rozovski, Uri, additional, Pasvolsky, Oren, additional, Wolach, Ofir, additional, Ram, Ron, additional, Amit, Odelia, additional, Zuckerman, Tsila, additional, Pek, Anat, additional, Rubinstein, Maly, additional, Sela-Navon, Michal, additional, Raanani, Pia, additional, and Shargian, Liat, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results